Fifty-three trials enrolling 20,312 and 13,569 patients for DPP-4 inhibitors and comparators, respectively, were included, reporting 176 malignancies, 257 MACEs, and 22 pancreatitis. The gene discussed is DPP4; the disease is pancreatitis.